The Filings Report

Amgen Inc

AMGNNasdaqCIK 318154Healthcare / Biotechnologyfiscal year ends December73 quarters since 2008

Revenue, Q2 FY2026
$10.1B
+9.5% on Q2 FY2025
Net income
$2.4B
+65.9% on Q2 FY2025
Free cash flow
$3.5B
+82.6% on Q2 FY2025
Diluted EPS
$4.37
+64.9% on Q2 FY2025
Revenue, TTM
$38.1B
trailing four quarters
Net margin, TTM
23.0%
net income $8.7B
Free cash flow, TTM
$10.2B
$12.5B less $2.3B capex
Cash and equivalents
$14.0B
long-term debt $51.9B, Jun 30, 2026
Shares, 12-month change
+0.4%
541M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$5.3B
2.1% of market value
Market value
$251.9B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Amgen Inc reported revenue of $10.1B, +9.5% on Q2 FY2025, and net income of $2.4B (+65.9%). Operating margin was 35.0%. Free cash flow, operating cash flow less capital expenditures, was $3.5B ($4.0B less $513M). Diluted earnings per share were $4.37.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
−$5B$0$5B$10B$15BQ3'22, Revenue: $6.7BQ3'22, Net income: $2.1BQ3'22Q4'22, Revenue: $6.8BQ4'22, Net income: $1.6BQ4'22Q1'23, Revenue: $6.1BQ1'23, Net income: $2.8BQ1'23Q2'23, Revenue: $7.0BQ2'23, Net income: $1.4BQ2'23Q3'23, Revenue: $6.9BQ3'23, Net income: $1.7BQ3'23Q4'23, Revenue: $8.2BQ4'23, Net income: $767MQ4'23Q1'24, Revenue: $7.4BQ1'24, Net income: −$113MQ1'24Q2'24, Revenue: $8.4BQ2'24, Net income: $746MQ2'24Q3'24, Revenue: $8.5BQ3'24, Net income: $2.8BQ3'24Q4'24, Revenue: $9.1BQ4'24, Net income: $627MQ4'24Q1'25, Revenue: $8.1BQ1'25, Net income: $1.7BQ1'25Q2'25, Revenue: $9.2BQ2'25, Net income: $1.4BQ2'25Q3'25, Revenue: $9.6BQ3'25, Net income: $3.2BQ3'25Q4'25, Revenue: $9.9BQ4'25, Net income: $1.3BQ4'25Q1'26, Revenue: $8.6BQ1'26, Net income: $1.8BQ1'26Q2'26, Revenue: $10.1BQ2'26, Net income: $2.4BQ2'26−$5B$0$5B$10B$15BQ3'22, Revenue: $6.7BQ3'22, Net income: $2.1BQ4'22, Revenue: $6.8BQ4'22, Net income: $1.6BQ4'22Q1'23, Revenue: $6.1BQ1'23, Net income: $2.8BQ2'23, Revenue: $7.0BQ2'23, Net income: $1.4BQ2'23Q3'23, Revenue: $6.9BQ3'23, Net income: $1.7BQ4'23, Revenue: $8.2BQ4'23, Net income: $767MQ4'23Q1'24, Revenue: $7.4BQ1'24, Net income: −$113MQ2'24, Revenue: $8.4BQ2'24, Net income: $746MQ2'24Q3'24, Revenue: $8.5BQ3'24, Net income: $2.8BQ4'24, Revenue: $9.1BQ4'24, Net income: $627MQ4'24Q1'25, Revenue: $8.1BQ1'25, Net income: $1.7BQ2'25, Revenue: $9.2BQ2'25, Net income: $1.4BQ2'25Q3'25, Revenue: $9.6BQ3'25, Net income: $3.2BQ4'25, Revenue: $9.9BQ4'25, Net income: $1.3BQ4'25Q1'26, Revenue: $8.6BQ1'26, Net income: $1.8BQ2'26, Revenue: $10.1BQ2'26, Net income: $2.4BQ2'26

Net income losses drawn in red.

Free cash flow
$0$2B$4B$6BQ3'22, Free cash flow: $2.8BQ3'22Q4'22, Free cash flow: $2.3BQ4'22Q1'23, Free cash flow: $720MQ1'23Q2'23, Free cash flow: $3.8BQ2'23Q3'23, Free cash flow: $2.5BQ3'23Q4'23, Free cash flow: $289MQ4'23Q1'24, Free cash flow: $459MQ1'24Q2'24, Free cash flow: $2.2BQ2'24Q3'24, Free cash flow: $3.3BQ3'24Q4'24, Free cash flow: $4.4BQ4'24Q1'25, Free cash flow: $980MQ1'25Q2'25, Free cash flow: $1.9BQ2'25Q3'25, Free cash flow: $4.2BQ3'25Q4'25, Free cash flow: $961MQ4'25Q1'26, Free cash flow: $1.5BQ1'26Q2'26, Free cash flow: $3.5BQ2'26$0$2B$4B$6BQ3'22, Free cash flow: $2.8BQ4'22, Free cash flow: $2.3BQ4'22Q1'23, Free cash flow: $720MQ2'23, Free cash flow: $3.8BQ2'23Q3'23, Free cash flow: $2.5BQ4'23, Free cash flow: $289MQ4'23Q1'24, Free cash flow: $459MQ2'24, Free cash flow: $2.2BQ2'24Q3'24, Free cash flow: $3.3BQ4'24, Free cash flow: $4.4BQ4'24Q1'25, Free cash flow: $980MQ2'25, Free cash flow: $1.9BQ2'25Q3'25, Free cash flow: $4.2BQ4'25, Free cash flow: $961MQ4'25Q1'26, Free cash flow: $1.5BQ2'26, Free cash flow: $3.5BQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$20B$40B$60B$80BQ3'22, Cash and equivalents: $9.5BQ3'22, Long-term debt: $37.2BQ3'22Q4'22, Cash and equivalents: $7.6BQ4'22, Long-term debt: $37.4BQ4'22Q1'23, Cash and equivalents: $31.6BQ1'23, Long-term debt: $60.8BQ1'23Q2'23, Cash and equivalents: $34.2BQ2'23, Long-term debt: $59.4BQ2'23Q3'23, Cash and equivalents: $34.7BQ3'23, Long-term debt: $59.0BQ3'23Q4'23, Cash and equivalents: $10.9BQ4'23, Long-term debt: $63.2BQ4'23Q1'24, Cash and equivalents: $9.7BQ1'24, Long-term debt: $60.1BQ1'24Q2'24, Cash and equivalents: $9.3BQ2'24, Long-term debt: $57.1BQ2'24Q3'24, Cash and equivalents: $9.0BQ3'24, Long-term debt: $56.9BQ3'24Q4'24, Cash and equivalents: $12.0BQ4'24, Long-term debt: $56.5BQ4'24Q1'25, Cash and equivalents: $8.8BQ1'25, Long-term debt: $54.0BQ1'25Q2'25, Cash and equivalents: $8.0BQ2'25, Long-term debt: $53.8BQ2'25Q3'25, Cash and equivalents: $9.4BQ3'25, Long-term debt: $52.4BQ3'25Q4'25, Cash and equivalents: $9.1BQ4'25, Long-term debt: $50.0BQ4'25Q1'26, Cash and equivalents: $12.0BQ1'26, Long-term debt: $51.9BQ1'26Q2'26, Cash and equivalents: $14.0BQ2'26, Long-term debt: $51.9BQ2'26$0$20B$40B$60B$80BQ3'22, Cash and equivalents: $9.5BQ3'22, Long-term debt: $37.2BQ4'22, Cash and equivalents: $7.6BQ4'22, Long-term debt: $37.4BQ4'22Q1'23, Cash and equivalents: $31.6BQ1'23, Long-term debt: $60.8BQ2'23, Cash and equivalents: $34.2BQ2'23, Long-term debt: $59.4BQ2'23Q3'23, Cash and equivalents: $34.7BQ3'23, Long-term debt: $59.0BQ4'23, Cash and equivalents: $10.9BQ4'23, Long-term debt: $63.2BQ4'23Q1'24, Cash and equivalents: $9.7BQ1'24, Long-term debt: $60.1BQ2'24, Cash and equivalents: $9.3BQ2'24, Long-term debt: $57.1BQ2'24Q3'24, Cash and equivalents: $9.0BQ3'24, Long-term debt: $56.9BQ4'24, Cash and equivalents: $12.0BQ4'24, Long-term debt: $56.5BQ4'24Q1'25, Cash and equivalents: $8.8BQ1'25, Long-term debt: $54.0BQ2'25, Cash and equivalents: $8.0BQ2'25, Long-term debt: $53.8BQ2'25Q3'25, Cash and equivalents: $9.4BQ3'25, Long-term debt: $52.4BQ4'25, Cash and equivalents: $9.1BQ4'25, Long-term debt: $50.0BQ4'25Q1'26, Cash and equivalents: $12.0BQ1'26, Long-term debt: $51.9BQ2'26, Cash and equivalents: $14.0BQ2'26, Long-term debt: $51.9BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Amgen Inc income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue10,0548,6189,8669,5579,1798,1499,0868,503+9.5%
Cost of revenue2,8112,7442,9763,0823,0112,9683,1123,310−6.6%
Gross profit—————————
Research and development1,8681,7192,1421,9001,7441,4861,7241,450+7.1%
Selling, general and administrative1,7451,6021,9521,7201,6911,6871,8781,625+3.2%
Operating income3,5142,6662,7202,5262,6561,1782,3112,047+32.3%
Other income (expense)(73)75(553)2,080(394)1,518(782)1,830+81.5%
Pretax income2,7682,0841,5143,9211,5681,9737823,101+76.5%
Income tax393265181705136243155271+189.0%
Net income2,3751,8191,3333,2161,4321,7306272,830+65.9%
Diluted EPS ($)4.373.34—5.932.653.20—5.22+64.9%
Diluted shares (millions)544544—542541541—542—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Amgen Inc balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents13,98912,0389,1299,4458,0288,81011,9739,011+74.3%
Short-term investments—————————
Total current assets34,96131,47529,05727,88526,73426,92929,03026,766+30.8%
Total assets95,63992,50490,58690,14187,89789,36791,83990,883+8.8%
Total current liabilities25,50224,95525,48921,79120,47623,00823,09920,312+24.5%
Long-term debt51,85951,88650,00552,43453,76054,01356,54956,854−3.5%
Total liabilities—————————
Stockholders’ equity11,6889,1908,6589,6197,4286,2075,8777,527+57.4%
Shares outstanding (millions)541540539538538538537538—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Amgen Inc cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow4,0022,1891,6034,6842,2801,3914,7713,571+75.5%
Capital expenditures513712642436369411371257+39.0%
Free cash flow (CFO − capex)3,4891,4779614,2481,9119804,4003,314+82.6%
Depreciation and amortization2221,116withheldwithheldwithheldwithheldwithheldwithheld—
Share repurchases—————————
Dividends paid1,3621,3581,2831,2821,2801,2791,2051,210+6.4%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 13, 2026.

Income statement

Amgen Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 16, 2022FY2020ended Dec 31, 2020filed Feb 9, 2021FY2019ended Dec 31, 2019filed Feb 12, 2020FY2018ended Dec 31, 2018filed Feb 13, 2019FY2017ended Dec 31, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 31, 2015filed Feb 16, 2016FY2014ended Dec 31, 2014filed Feb 19, 2015FY2013ended Dec 31, 2013filed Feb 24, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Feb 25, 2011FY2009ended Dec 31, 2009filed Mar 1, 2010FY2008ended Dec 31, 2008filed Aug 10, 2009FY2007ended Dec 31, 2007filed Aug 10, 2009
Revenue36,75133,42428,19026,32325,97925,42423,36223,74722,84922,99121,66220,06318,67617,26515,58215,05314,64215,00314,771
Cost of revenue12,03712,8588,4516,4066,4546,1594,3564,1014,0694,162—————————
Gross profit———————————————————
Research and development7,2725,9644,7844,4344,8194,2074,1163,7373,5623,8404,0704,2974,0833,3803,1672,8942,8643,0303,266
Selling, general and administrative7,0507,0966,1795,4145,3685,7305,1505,3324,8705,0624,8464,6995,1844,8144,4993,9833,8203,7893,361
Operating income9,0807,2587,8979,5667,6399,1399,67410,2639,9739,7948,4706,1915,8675,5774,3125,5455,5065,2143,980
Other income (expense)2,6515062,833(814)259256753674928629603465420485448376276352309
Pretax income8,9764,6097,8557,3466,7018,1339,1389,5459,5979,1637,9785,5855,2655,0094,1505,3175,2045,0153,793
Income tax1,2655191,1387948088691,2961,1517,6181,4411,039427184664467690599963715
Net income7,7114,0906,7176,5525,8937,2647,8428,3941,9797,7226,9395,1585,0814,3453,6834,6274,6054,0523,078
Diluted EPS ($)14.237.5612.4912.1110.2812.3112.8812.622.6910.249.066.706.645.524.044.794.513.772.74
Diluted shares (millions)5425415385415735906096657357547667707657879129651,0211,0751,123

Balance sheet

Amgen Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 16, 2022FY2020ended Dec 31, 2020filed Feb 9, 2021FY2019ended Dec 31, 2019filed Feb 12, 2020FY2018ended Dec 31, 2018filed Feb 13, 2019FY2017ended Dec 31, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 31, 2015filed Feb 16, 2016FY2014ended Dec 31, 2014filed Feb 19, 2015FY2013ended Dec 31, 2013filed Feb 24, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Feb 25, 2011FY2009ended Dec 31, 2009filed Mar 1, 2010FY2008ended Dec 31, 2008filed Aug 10, 2009FY2007ended Dec 31, 2007filed Aug 10, 2009
Cash and equivalents9,12911,97310,9447,6297,9896,2666,0376,9453,8003,2414,1443,7313,8053,2576,9463,2872,8841,7742,024
Short-term investments——01,676484,3812,87422,35937,878——————————
Total current assets29,05729,03030,33222,18619,38521,14418,44037,61849,47646,01038,51534,71327,36731,20927,59323,12918,93215,221—
Total assets90,58691,83997,15465,12161,16562,94859,70766,41679,95477,62671,44969,00966,12554,29848,87143,48639,62936,427—
Total current liabilities25,48923,09918,39215,68712,18411,65312,83513,4889,02011,2048,6647,0087,9478,1915,7546,5703,8734,886—
Long-term debt50,00556,54963,17037,35433,22232,89526,95029,51034,19030,19329,18230,21529,62326,52921,42813,36210,601——
Total liabilities———————————————————
Stockholders’ equity8,6585,8776,2323,6616,7009,4099,67312,50025,24129,87528,08325,77822,09619,06019,02923,94422,66720,88518,512
Shares outstanding (millions)539537536534557578590622721736752759755748791932979——

Cash flow statement

Amgen Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 14, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 16, 2022FY2020ended Dec 31, 2020filed Feb 9, 2021FY2019ended Dec 31, 2019filed Feb 12, 2020FY2018ended Dec 31, 2018filed Feb 13, 2019FY2017ended Dec 31, 2017filed Feb 13, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 31, 2015filed Feb 16, 2016FY2014ended Dec 31, 2014filed Feb 19, 2015FY2013ended Dec 31, 2013filed Feb 24, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Feb 25, 2011FY2009ended Dec 31, 2009filed Mar 1, 2010FY2008ended Dec 31, 2008filed Aug 10, 2009FY2007ended Dec 31, 2007filed Aug 10, 2009
Operating cash flow9,95811,4908,4719,7219,26110,4979,15011,29611,17710,3549,7318,9526,2915,8825,1195,7876,3365,9885,401
Capital expenditures1,8581,0961,1129368806086187386647385947186936895675805306721,267
Free cash flow (CFO − capex)8,10010,3947,3598,7858,3819,8898,53210,55810,5139,6169,1378,2345,5985,1934,5525,2075,8065,3164,134
Depreciation and amortization5,1675,5924,0713,4173,3983,6012,2061,9461,9552,1052,1082,0921,2861,0881,0601,0171,0491,0731,202
Share repurchases020006,3604,9753,4867,70217,7943,1602,9651,8671388324,6078,3153,7863,2082,2685,100
Dividends paid5,1244,8324,5564,1964,0133,7553,5093,5073,3652,9982,3961,8511,4151,11850000——

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$4M
6 sales by 3 insiders; officers and directors $4M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$29M
14 sales by 6 insiders; officers and directors $29M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Aug 13, 2026Khosla RachnaSVP, Business Developmentoption exercise1,252$162.60$204K7,656Aug 13, 2026
Aug 13, 2026Khosla RachnaSVP, Business Developmentopen-market sale1,252$416.43$521K6,404Aug 13, 2026
Aug 11, 2026Khosla RachnaSVP, Business Developmentopen-market sale2,000$412.57$825K6,404Aug 13, 2026
Aug 7, 2026Busch Matthew C.VP, Finance & CAOaward730$0.00—5,080Aug 12, 2026
Aug 7, 2026Ishrak OmarDirectoraward85$0.00—7,486Aug 10, 2026
Aug 7, 2026Holley Charles MDirectoraward103$0.00—12,990Aug 10, 2026
Aug 7, 2026Drake Michael VDirectoraward64$0.00—5,876Aug 10, 2026
Aug 6, 2026Miller DerekSVP, Human Resourcesoption exercise2,069$162.60$336K14,531Aug 7, 2026
Aug 6, 2026Miller DerekSVP, Human Resourcesopen-market sale2,069$402.54$833K12,462Aug 7, 2026
Aug 6, 2026Miller DerekSVP, Human Resourcesoption exercise1,821$177.46$323K14,283Aug 7, 2026
Aug 6, 2026Miller DerekSVP, Human Resourcesopen-market sale1,821$402.54$733K12,462Aug 7, 2026
Aug 6, 2026Grygiel Nancy A.SVP & CCOoption exercise1,970$177.46$350K9,310Aug 7, 2026
Aug 6, 2026Grygiel Nancy A.SVP & CCOopen-market sale1,970$402.16$792K7,340Aug 7, 2026
Aug 6, 2026Grygiel Nancy A.SVP & CCOoption exercise1,000$177.31$177K8,340Aug 7, 2026
Aug 6, 2026Grygiel Nancy A.SVP & CCOopen-market sale1,000$402.16$402K7,340Aug 7, 2026
May 19, 2026Miles Amy EDirectoraward665$0.00—5,640May 21, 2026
May 19, 2026Kullman Ellen JamisonDirectoraward665$0.00—14,536May 21, 2026
May 19, 2026Klotman Mary E.Directoraward665$0.00—2,211May 21, 2026
May 19, 2026Jacks TylerDirectoraward665$0.00—18,284May 21, 2026
May 19, 2026Ishrak OmarDirectoraward665$0.00—7,359May 21, 2026
May 19, 2026Holley Charles MDirectoraward665$0.00—12,799May 21, 2026
May 19, 2026Garland Greg C.Directoraward665$0.00—13,848May 21, 2026
May 19, 2026Eckert RobertDirectoraward665$0.00—26,251May 21, 2026
May 19, 2026Druker BrianDirectoraward665$0.00—8,391May 21, 2026
May 19, 2026Drake Michael VDirectoraward665$0.00—5,774May 21, 2026

Full insider history for Amgen Inc, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Amgen Inc., CIK 318154 on EDGAR
Extract generated
August 27, 2026
Withheld
2 line-years whose four quarters do not sum to the filed year: depreciation amortization FY2024, depreciation amortization FY2025
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/AMGN.json